Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study

被引:11
作者
Kim, Kiwon [1 ,2 ]
Jang, Eun Hye [3 ]
Kim, Ah Young [3 ]
Fava, Maurizio [4 ]
Mischoulon, David [4 ]
Papakostas, George, I [4 ]
Kim, Hyewon [2 ]
Na, Eun Jin [2 ]
Yu, Han Young [3 ]
Jeon, Hong Jin [2 ,5 ,6 ]
机构
[1] Vet Hlth Serv Med Ctr, Dept Psychiat, Seoul, South Korea
[2] Sungkyunkwan Univ, Depress Ctr, Samsung Med Ctr, Sch Med,Dept Psychiat, Seoul, South Korea
[3] Elect & Telecommun Res Inst, Biomed IT Convergence Res Div, Gwangju, South Korea
[4] Harvard Med Sch, Depress Clin & Res Program, Massachusetts Gen Hosp, Boston, MA 02115 USA
[5] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Dept Med Device Management & Res, 81 Irwon Ro, Seoul 06351, South Korea
[6] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Clin Res Design & Evaluat, 81 Irwon Ro, Seoul 06351, South Korea
基金
新加坡国家研究基金会;
关键词
Panic attack; Major depression disorder; Panic disorder; IL-6; Leptin; ANXIETY DISORDERS; DSM-IV; ATTACKS; LEPTIN; POPULATION; CYTOKINES; INTERLEUKIN-6; NEUROGENESIS; METABOLISM; PSYCHIATRY;
D O I
10.1016/j.comppsych.2019.152140
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Peripheral biomarkers have been studied to predict treatment response of panic symptoms. We hypothesized that depressive disorder (MDD) vs. panic disorder (PD) would exhibit different peripheral biomarkers, and their correlation with severity of panic attacks (PA) would also differ. Methods: Forty-one MDD patients, 52 PD patients, and 59 healthy controls were followed for 12 weeks. We measured peripheral biomarkers along with the Panic Disorder Severity Scale (PDSS) at each visit-pre-treatment, 2, 4, 8, and 12 weeks on a regular schedule. Peripheral biomarkers including serum cytokines, plasma and serum brain-derived neurotrophic factor (BDNF), leptin, adiponectin, and C-reactive protein (CRP) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: Patients with MDD and PD demonstrated significantly higher levels of pre-treatment IL-6 compared to controls, but no differences were seen in plasma and serum BDNF, leptin, adiponectin, and CRP. Pre-treatment leptin showed a significant clinical correlation with reduction of panic symptoms in MDD patients at visit 5 (p = 0.011), whereas pre-treatment IL-6 showed a negative correlation with panic symptom reduction in PD patients (p = 0.022). An improvement in three panic-related items was observed to be positively correlated with pre-treatment leptin in MDD patients: distress during PA, anticipatory anxiety, and occupational interference. Conclusion: Higher pre-treatment leptin was associated with better response to treatment regarding panic symptoms in patients with MDD, while higher IL-6 was associated with worse response regarding panic symptoms in PD patients. Different predictive peripheral biomarkers observed in MDD and PD suggest the need for establishing individualized predictive biomarkers, even in cases of similar symptoms observed in different disorders. (C) 2019 The Author( s). Published by Elsevier Inc.
引用
收藏
页数:8
相关论文
共 64 条
  • [1] Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization
    Amur, S.
    LaVange, L.
    Zineh, I.
    Buckman-Garner, S.
    Woodcock, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 34 - 46
  • [2] A putative role for cytokines in the impaired appetite in depression
    Andreasson, Anna
    Arborelius, Lotta
    Erlanson-Albertsson, Charlotte
    Lekander, Mats
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2007, 21 (02) : 147 - 152
  • [3] Review of diagnostic, prognostic, and predictive biomarkers in melanoma
    Ankeny, Jacob S.
    Labadie, Brian
    Luke, Jason
    Hsueh, Eddy
    Messina, Jane
    Zager, Jonathan S.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (5-6) : 487 - 493
  • [4] [Anonymous], 2016, BEST (Biomarkers, EndpointS, and other Tools) Resource
  • [5] PANIC DISORDER AND AGORAPHOBIA: AN OVERVIEW AND COMMENTARY ON DSM-5 CHANGES
    Asmundson, Gordon J. G.
    Taylor, Steven
    Smits, Jasper A. J.
    [J]. DEPRESSION AND ANXIETY, 2014, 31 (06) : 480 - 486
  • [6] Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses
    Audet, Marie-Claude
    Anisman, Hymie
    [J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
  • [7] Panic Attacks as a Dimension of Psychopathology: Evidence for Associations With Onset and Course of Mental Disorders and Level of Functioning
    Batelaan, Neeltje M.
    Rhebergen, Didi
    de Graaf, Ron
    Spijker, Jan
    Beekman, Aartjan T. F.
    Penninx, Brenda W. J. H.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (09) : 1195 - 1202
  • [8] Cytokine Levels in Panic Disorder: Evidence for a Dose-Response Relationship
    Belem da Silva, Cristiano Tschiedel
    Costa, Marianna de Abreu
    Bortoluzzi, Andressa
    Pfaffenseller, Bianca
    Vedana, Flavia
    Kapczinski, Flavio
    Manfro, Gisele Gus
    [J]. PSYCHOSOMATIC MEDICINE, 2017, 79 (02): : 126 - 132
  • [9] A way forward for research on biomarkers for psychiatric disorders
    Boksa, Patricia
    [J]. JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2013, 38 (02): : 75 - 77
  • [10] The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
    Cagney, Daniel N.
    Sul, Joohee
    Huang, Raymond Y.
    Ligon, Keith L.
    Wen, Patrick Y.
    Alexander, Brian M.
    [J]. NEURO-ONCOLOGY, 2018, 20 (09) : 1162 - 1172